Orion (ORNBV) Stock Price, Fundamentals & Analysis

What ORNBV does

Orion (ORNBV) is a stock listed on the Nasdaq Helsinki exchange in the Healthcare sector, specifically the Drug Manufacturers – General industry. Headquartered in Espoo, Finland, the company develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) across Finland, Scandinavia, the rest of Europe, North America, and internationally. Its portfolio includes treatments for prostate cancer, Parkinson's disease, inflammatory pain, menopausal symptoms, heart failure, breast cancer, asthma, and rheumatoid arthritis. Orion is part of the Nasdaq Helsinki stocks universe and operates alongside peers such as Daiichi Sankyō (4568), Shionogi (4507), and Chong Kun Dang (185750).

Key numbers explained

• The current price of 82.95 EUR reflects the latest trading value; the +0.06% change today shows the intraday move.
• The trailing P/E ratio of 19.8 divides the current price by the last 12 months of earnings per share (4.18 EUR), indicating how much investors pay per euro of recent earnings.
• The forward P/E ratio of 17.5 uses expected future earnings, offering a look at valuation relative to analyst expectations.
• The dividend yield of 2.17% shows the annual dividend as a percentage of the current price, with an ex-dividend date of 19 Oct 2026 marking the cutoff for eligibility.
• Orion pays out 41% of its trailing earnings as dividends, a measure of how much profit is returned to shareholders.
• The beta of 0.3 suggests the stock has historically moved less than the broader market, often interpreted as lower volatility.
• The 52-week range of 56.5 – 84.1 EUR shows the lowest and highest prices over the past year, with the current price near the upper end.
• The price-to-book ratio of 9.21 compares the market price to the company's book value per share, a common way to assess whether a stock trades at a premium to its accounting value.

What to watch

Orion's stock can be influenced by factors common to the pharmaceutical sector and the Nordic market. Investors often monitor upcoming earnings releases, with the next report scheduled for 28 Oct 2026, as results can shift sentiment. The company's revenue growth of 25.2% year over year and strong margins (profit margin 28.5%, operating margin 33.8%) are worth tracking alongside product-cycle developments and regulatory changes. Broader movements in the OMX Helsinki 25 index, currency fluctuations, and healthcare policy shifts can also affect the share price.